Valneva Se ADR (VALN)

$6.38 -0.07 (-1.09%)
Market Cap 539.45M
Revenue (ttm) 183.50M
Net Income (ttm) -13.25M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7.22%
Debt to Equity Ratio 1.03
Volume 5,900
Avg Vol 65,878
Day's Range N/A - N/A
Shares Out 83.64M
Stochastic %K 36%
Beta 1.85
Analysts Strong Sell
Price Target $13.85

Latest News on VALN

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

May 12, 2025, 1:00 AM EDT - 2 days ago

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

Valneva SE (VALN) Q1 2025 Earnings Call Transcript

May 9, 2025, 9:47 AM EDT - 4 days ago

Valneva SE (VALN) Q1 2025 Earnings Call Transcript

Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance

May 8, 2025, 12:30 AM EDT - 6 days ago

Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance

Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

May 7, 2025, 11:45 AM EDT - 6 days ago

Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people

May 7, 2025, 8:40 AM EDT - 6 days ago

Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people

Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 7, 2025, 1:00 AM EDT - 7 days ago

Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

Apr 26, 2025, 1:10 PM EDT - 17 days ago

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Apr 18, 2025, 4:00 AM EDT - 26 days ago

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

Apr 16, 2025, 11:45 AM EDT - 27 days ago

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine

Apr 14, 2025, 2:28 PM EDT - 4 weeks ago

Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine

Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country

Apr 14, 2025, 11:45 AM EDT - 4 weeks ago

Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

Apr 9, 2025, 1:00 AM EDT - 5 weeks ago

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm

Apr 7, 2025, 9:33 AM EDT - 5 weeks ago

VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm

Valneva SE Shareholding Declaration - March 2025

Apr 3, 2025, 11:45 AM EDT - 5 weeks ago

Valneva SE Shareholding Declaration - March 2025

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above

Apr 1, 2025, 11:45 AM EDT - 6 weeks ago

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above

Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA

Mar 31, 2025, 1:00 AM EDT - 6 weeks ago

Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA

Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program

Mar 26, 2025, 1:00 PM EDT - 6 weeks ago

Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program

Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F

Mar 25, 2025, 2:00 AM EDT - 7 weeks ago

Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F

Valneva Responds to French Government's Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion

Mar 24, 2025, 2:00 AM EDT - 7 weeks ago

Valneva Responds to French Government's Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion

Valneva SE (VALN) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 8:00 PM EDT - 7 weeks ago

Valneva SE (VALN) Q4 2024 Earnings Call Transcript

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Stockholders to Learn More About the Investigation

Mar 20, 2025, 10:00 AM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Stockholders to Learn More About the Investigation

Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

Mar 20, 2025, 2:00 AM EDT - 7 weeks ago

Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Shareholders to Reach Out

Mar 19, 2025, 10:00 AM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation

Mar 18, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation

Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Mar 17, 2025, 10:00 AM EDT - 2 months ago

Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Shareholders to Inquire about Securities Investigation

Mar 16, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect

Mar 14, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Stockholders to Inquire about Securities Investigation

Mar 13, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Investors to Learn More About the Investigation

Mar 12, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Investors to Learn More About the Investigation

Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Mar 11, 2025, 10:00 AM EDT - 2 months ago

Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Stockholders to Connect

Mar 9, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Stockholders to Connect

Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Mar 7, 2025, 10:00 AM EST - 2 months ago

Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Stockholders to Learn More About the Investigation.

Mar 6, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Stockholders to Learn More About the Investigation.

Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Investors to Inquire about Securities Investigation

Mar 5, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Investors to Reach Out

Mar 4, 2025, 1:45 PM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Investors to Reach Out

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

Mar 3, 2025, 1:00 AM EST - 2 months ago

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

Valneva Receives EMA's Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®

Feb 28, 2025, 11:45 AM EST - 2 months ago

Valneva Receives EMA's Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®

Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook

Feb 18, 2025, 1:00 AM EST - 3 months ago

Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook

Valneva Receives Marketing Authorization in the UK for the World's First Chikungunya Vaccine, IXCHIQ®

Feb 5, 2025, 1:00 AM EST - 3 months ago

Valneva Receives Marketing Authorization in the UK for the World's First Chikungunya Vaccine, IXCHIQ®

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million

Jan 30, 2025, 11:45 AM EST - 3 months ago

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million

Valneva Is A 'Buy' As A First-Mover In Chikungunya

Jan 23, 2025, 3:48 PM EST - 3 months ago

Valneva Is A 'Buy' As A First-Mover In Chikungunya

Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision

Jan 22, 2025, 11:45 AM EST - 3 months ago

Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision

Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot

Jan 21, 2025, 10:44 AM EST - 4 months ago

Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot

Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine

Jan 20, 2025, 11:45 AM EST - 4 months ago

Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

Jan 6, 2025, 11:45 AM EST - 4 months ago

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference